Moderna Inc (MRNA)

[axelvento]

this company isn't likely to depend on the vaccine for very long. Moderna has several candidates across treatment areas in late-stage development. And the company recently said it aims to launch as many as 15 products over the coming five years.

If Moderna succeeds, this could be big, catapulting the company to annual revenue of as much as $30 billion a few years after launch. These potential products span the areas of oncology, rare diseases, and, of course, respiratory diseases such as the coronavirus. The closest to market include a vaccine candidate for respiratory syncytial virus and a combination shot to prevent coronavirus and flu. They could launch in 2024 and 2025